title: Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy.
abstract: The Kattan postoperative radical prostatectomy (RP) nomogram is used to predict biochemical recurrence-free progression (BCRFP) after RP. However, external validation among contemporary patients using modern outcome definitions is limited.
  
  
  
  A total of 1,931 patients who underwent RP at Roswell Park Cancer Institute (RPCI) between 1993 and 2014 (median follow-up, 47 months; range, 0-244 months) were assessed for NCCN-defined biochemical failure (BF) and RPCI-defined treatment failure (TF). Actual rates of biochemical failure-free survival (BFS; defined as 1 - BF) and treatment failure-free survival (TFS; defined as 1 - TF) were compared with Kattan BCRFP nomogram predictions.
  
  
  
  The Kattan BCRFP nomogram predictions at 5 and 10 years were predictive of BFS (area under the receiver operating characteristic curve [AUC], 0.772) and TFS (AUC, 0.774). The Kattan BCRFP nomogram tended to underestimate BFS and TFS compared with actual outcomes. The Kattan 5-year BCRFP predictions consistently overestimated actual 5-year BFS outcomes among subgroups of high- and intermediate-risk patients with at least 5-year outcomes.
  
  
  
  The Kattan BCRFP nomogram is a robust predictor of NCCN-defined BF in a large sample of patients with RP with substantial follow-up and modern, standardized failure definitions.
authors: From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.
authors: Rochelle Payne
authors: RP
authors: Ondracek
authors: From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.
authors: Michael W
authors: MW
authors: Kattan
authors: From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.|From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.
authors: Christine
authors: C
authors: Murekeyisoni
authors: From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.
authors: Changhong
authors: C
authors: Yu
authors: From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.|From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.|From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.
authors: Eric C
authors: EC
authors: Kauffman
authors: From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.
authors: James R
authors: JR
authors: Marshall
authors: From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.|From the Department of Cancer Prevention, Roswell Park Cancer Institute, Buffalo, New York; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; Department of Urology, Center for Immunotherapy, and Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; and Department of Urology, State University of New York at Buffalo, Buffalo, New York.
authors: James L
authors: JL
authors: Mohler
mesh_terms: D000368:Aged; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D049451:Nomograms; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000601:surgery*